Neuphoria Therapeutics Inc. Operating Expenses
Neuphoria Therapeutics Inc. (NEUP) reported Operating Expenses of $17.63 million for the 12-month period ending 2026-06-30, per its 10-K filed 2026-09-18.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingExpenses · last filed 2026-09-18
- Neuphoria Therapeutics Inc. operating expenses for the quarter ending 2026-06-30 was $6.70M, a 15.09% increase year-over-year.
- Neuphoria Therapeutics Inc. operating expenses for the quarter ending 2026-03-31 was $1.21M, a 59.92% decline year-over-year.
- Neuphoria Therapeutics Inc. operating expenses for the quarter ending 2025-12-31 was $4.06M, a 6.99% decline year-over-year.
- Neuphoria Therapeutics Inc. operating expenses for the quarter ending 2025-09-30 was $5.65M, a 58.44% increase year-over-year.
- Neuphoria Therapeutics Inc. operating expenses for fiscal 2026 was $17.63M, a 5.05% increase from fiscal 2025.
- Neuphoria Therapeutics Inc. operating expenses for fiscal 2025 was $16.78M, a 6.23% decline from fiscal 2024.
- Neuphoria Therapeutics Inc. operating expenses for fiscal 2024 was $17.89M, a 18.61% decline from fiscal 2023.
- Neuphoria Therapeutics Inc. operating expenses for fiscal 2023 was $21.98M.
| Period end | Operating Expenses 3 month | Operating Expenses 6 month | Operating Expenses 9 month | Operating Expenses 12 month |
|---|---|---|---|---|
| 2026-06-30 | $6.70M derived: 10-K 12 month − 10-Q 9 month · filed 2026-09-18 | $7.91M derived: sum of 2 quarters · filed 2026-09-18 | $11.97M derived: sum of 3 quarters · filed 2026-09-18 | $17.63M 10-K · filed 2026-09-18 |
| 2026-03-31 | $1.21M 10-Q · filed 2026-05-15 | $5.27M derived: sum of 2 quarters · filed 2026-05-15 | $10.93M 10-Q · filed 2026-05-15 | $16.75M derived: sum of 4 quarters · filed 2026-09-18 |
| 2025-12-31 | $4.06M 10-Q · filed 2026-02-17 | $9.71M 10-Q · filed 2026-02-17 | $15.54M derived: sum of 3 quarters · filed 2026-09-18 | $18.56M derived: sum of 4 quarters · filed 2026-09-18 |
| 2025-09-30 | $5.65M 10-Q · filed 2025-11-14 | $11.47M derived: sum of 2 quarters · filed 2026-09-18 | $14.50M derived: sum of 3 quarters · filed 2026-09-18 | $18.86M derived: sum of 4 quarters · filed 2026-09-18 |
| 2025-06-30 | $5.82M derived: 10-K 12 month − 10-Q 9 month · filed 2026-09-18 | $8.84M derived: sum of 2 quarters · filed 2026-09-18 | $13.21M derived: sum of 3 quarters · filed 2026-09-18 | $16.78M 10-K · filed 2026-09-18 |
| 2025-03-31 | $3.02M 10-Q · filed 2026-05-15 | $7.39M derived: sum of 2 quarters · filed 2026-05-15 | $10.96M 10-Q · filed 2026-05-15 | $16.43M derived: sum of 4 quarters · filed 2026-05-15 |
| 2024-12-31 | $4.37M 10-Q · filed 2026-02-17 | $7.93M 10-Q · filed 2026-02-17 | $13.41M derived: sum of 3 quarters · filed 2026-02-17 | $15.81M derived: sum of 4 quarters · filed 2026-02-17 |
| 2024-09-30 | $3.57M 10-Q · filed 2025-11-14 | $9.05M derived: sum of 2 quarters · filed 2025-11-14 | $11.44M derived: sum of 3 quarters · filed 2025-11-14 | $15.99M derived: sum of 4 quarters · filed 2025-11-14 |
| 2024-06-30 | $5.48M derived: 10-K 12 month − 10-Q 9 month · filed 2025-09-29 | $7.87M derived: sum of 2 quarters · filed 2025-09-29 | $12.42M derived: sum of 3 quarters · filed 2025-09-29 | $17.89M 10-K · filed 2025-09-29 |
| 2024-03-31 | $2.39M 10-Q · filed 2025-05-20 | $6.95M derived: sum of 2 quarters · filed 2025-05-20 | $12.41M 10-Q · filed 2025-05-20 | |
| 2023-12-31 | $4.55M 10-Q · filed 2025-02-14 | $10.02M 10-Q · filed 2025-02-14 | ||
| 2023-09-30 | $5.47M 10-Q · filed 2024-11-14 | |||
| 2023-06-30 | $21.98M 10-K · filed 2024-09-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Marker Therapeutics, Inc. (MRKR) | United States | $0.020B | -2.86 |
| Cellectar Biosciences, Inc. (CLRB) | United States | $0.020B | -1.03 |
| Shuttle Pharmaceuticals Holdings, Inc. (SHPH) | United States | $0.019B | -0.31 |
| Rocket One Inc. (RKTO) | United States | $0.019B | |
| ATOSSA THERAPEUTICS, INC. (ATOS) | United States | $0.021B | -0.52 |
| Cocrystal Pharma, Inc. (COCP) | United States | $0.022B | |
| Biofrontera Inc. (BFRI) | United States | $0.018B | -2.13 |
| Lipocine Inc. (LPCN) | United States | $0.017B | -1.79 |
| PALATIN TECHNOLOGIES INC (PTN) | United States | $0.017B | -5.36 |
| Allarity Therapeutics, Inc. (ALLR) | United States | $0.017B | -1.66 |